Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Immunoconjugates × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4 Lymphoid 3 Gastrointestinal 3 Tumor-Agnostic 2 Plasma cell 1 Genitourinary 1 CNS 1

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

Dexamethasone 728 Bortezomib 404 Lenalidomide 391 Cyclophosphamide 312 Melphalan 240 Calcium Dobesilate 216 daratumumab 201 pomalidomide 172 carfilzomib 151 fludarabine 114 Thalidomide 107 fludarabine phosphate 105 Filgrastim 99 Peripheral Blood Stem Cell Transplantation 98 ixazomib 80 Whole-Body Irradiation 74 Granulocyte Colony-Stimulating Factor 74 dexamethasone acetate 73 Mycophenolic Acid 70 Busulfan 70 dexamethasone 21-phosphate 61 Tacrolimus 61 Prednisone 58 auricularum 56 isatuximab 54 belantamab mafodotin 54 Cyclosporine 54 elotuzumab 53 Antilymphocyte Serum 47 Etoposide 45

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03489525 2022-03-28

MEDI2228

MedImmune LLC

Phase 1 Completed

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡